Vertex Pharmaceuticals Inc / Ma financial data

Symbol
VRTX on Nasdaq
Location
50 Northern Avenue, Boston, MA
State of incorporation
MA
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 280 % -32%
Quick Ratio 27 % +42.1%
Debt-to-equity 35.9 % +16.1%
Return On Assets -2.41 % -114%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 257M shares -0.59%
Common Stock, Shares, Outstanding 257M shares -0.29%
Entity Public Float 122B USD +34.3%
Common Stock, Value, Issued 2.6M USD 0%
Weighted Average Number of Shares Outstanding, Basic 258M shares +0.08%
Weighted Average Number of Shares Outstanding, Diluted 258M shares -1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 11B USD +11.7%
Costs and Expenses 11.3B USD +86.4%
Operating Income (Loss) -233M USD -106%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 249M USD -94.3%
Income Tax Expense (Benefit) 784M USD +3.14%
Net Income (Loss) Attributable to Parent -536M USD -115%
Earnings Per Share, Basic -2.08 USD/shares -115%
Earnings Per Share, Diluted -2.08 USD/shares -115%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.57B USD -55.9%
Marketable Securities, Current 1.55B USD +82.1%
Accounts Receivable, after Allowance for Credit Loss, Current 1.61B USD +2.94%
Inventory, Net 1.21B USD +63.2%
Other Assets, Current 76.4M USD -9.37%
Assets, Current 9.6B USD -32.2%
Deferred Income Tax Assets, Net 2.33B USD +28.6%
Operating Lease, Right-of-Use Asset 1.36B USD +362%
Intangible Assets, Net (Excluding Goodwill) 826M USD -1.67%
Goodwill 1.09B USD 0%
Other Assets, Noncurrent 999M USD +11.6%
Assets 22.5B USD -0.87%
Accounts Payable, Current 413M USD +13.2%
Employee-related Liabilities, Current 352M USD +19.4%
Accrued Liabilities, Current 2.79B USD +5.02%
Liabilities, Current 3.56B USD +0.49%
Operating Lease, Liability, Noncurrent 1.54B USD +343%
Other Liabilities, Noncurrent 902M USD +2.75%
Liabilities 6.12B USD +18.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 128M USD
Retained Earnings (Accumulated Deficit) 9.61B USD -5.28%
Stockholders' Equity Attributable to Parent 16.4B USD -6.66%
Liabilities and Equity 22.5B USD -0.87%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 1.31B USD +45.2%
Net Cash Provided by (Used in) Financing Activities -358M USD -21.3%
Net Cash Provided by (Used in) Investing Activities -2.14B USD -16.5%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 257M shares -0.29%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.2B USD +1.11%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.57B USD -55.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 10M USD -9.91%
Deferred Tax Assets, Valuation Allowance 273M USD +2.36%
Deferred Tax Assets, Gross 3.16B USD +29.8%
Operating Lease, Liability 1.63B USD +327%
Payments to Acquire Property, Plant, and Equipment 68.4M USD +62.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -394M USD -111%
Lessee, Operating Lease, Liability, to be Paid 2.74B USD +528%
Operating Lease, Liability, Current 87.1M USD +163%
Lessee, Operating Lease, Liability, to be Paid, Year Two 159M USD +283%
Lessee, Operating Lease, Liability, to be Paid, Year One 167M USD +297%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure +82.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 909M USD +1570%
Lessee, Operating Lease, Liability, to be Paid, Year Three 158M USD +291%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 706M USD +14.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 155M USD +324%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 53.5M USD +37.9%
Deferred Tax Assets, Net of Valuation Allowance 2.89B USD +33.2%
Share-based Payment Arrangement, Expense 699M USD +20.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%